ArticleCureus2021
Spindle Cell Squamous Cell Carcinoma of the Scalp Treated With Pembrolizumab Cisplatin and 5-Fluorouracil.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival outcomes and prognostic factors in spindle cell variants of squamous cell carcinoma: a machine learning analysis of 1086 patients from the SEER database.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous spindle cell squamous cell carcinoma (SpSCC) of the head and neck is a very rare tumor. It is an aggressive variant of squamous cell carcinoma. The usual treatment of the localized disease is surgery with or without radiotherapy. No standard treatment for metastatic disease although some case reports had reported the effectiveness of programmed cell death protein 1 (PD-1) blockade as a possible treatment. We are reporting a 57-year-old Arabic female presented with metastatic scalp spindle cell squamous carcinoma, who was treated with three lines of chemotherapy. She received pembrolizumab, cisplatin, and 5-fluorouracil for three cycles but did not respond, the pembrolizumab was dropped and we added cetuximab for three more cycles but did not respond also. She had a partial response to doxorubicin single agent as a third line. Our case showed resistance to pembrolizumab and cetuximab combined with chemotherapy regimens which are both considered as standard treatments for the classical squamous cell carcinoma of the head and neck, but there was a partial response to single-agent doxorubicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.